Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Regional REIT sells Clearblue Innovation Centre for £8.8m

(Sharecast News) - Regional REIT announced the sale of Bedford's Clearblue Innovation Centre for £8.8m on Thursday, achieving an 11.4% premium to its 30 June book value as part of its ongoing strategy to strengthen its balance sheet. The London-listed company said the disposal followed the completion of its asset management objectives for the property, which is leased to SPD Development Company and generates £860,000 in annual headline rent from 58,167 square feet of lettable space, delivering a net initial yield of 9.16%.

It noted that a lease extension to September 2033 had already been agreed, alongside £0.7m of asset management works due to complete in October that would improve the building's EPC rating to B from F at acquisition.

It said the measures had contributed to a £2.3m uplift in the asset's value.

Proceeds from the sale would be used to pay down debt.

"This disposal demonstrates the success of our active asset management strategy, delivering an 11.4% premium over book value and enhancing the quality of our portfolio," said Stephen Inglis, chief executive of London & Scottish Property Investment Management, the group's asset manager.

"The improvements made to the Clearblue Innovation Centre, including a lease extension and EPC upgrade, have significantly increased its value.

"The proceeds will further strengthen our balance sheet and position us to continue creating value through disciplined capital allocation and selective asset sales."

At 1419 BST, shares in Regional REIT were down 0.33% at 121.6p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.